-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The treatment of polycystic ovary syndrome (PCOS) should be based on pathophysiology.
The study included 23 PCOS adolescents and 21 control adolescents matched for age and BMI.
cholesterol
The results showed that compared with the control group, the level of HMGB1 in PCOS patients increased (19.
In summary, the results of this study show that the circulating HMGB1 levels of PCOS adolescents increased after MYO+ALA combination treatment, and the treatment effectively normalized HMGB1 levels.
Original source:
Francesca Cirillo, et al.
ncbi.
nlm.
nih.
gov/32054355/" target="_blank" rel="noopener">HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA) in this message